Hepatitis C

Data show the safety profile of Ustekinumab in long-term IBD pooled safety dataset was found favorable among bionaive patients.

A discussion on the role of PLSec-AFP for HCC risk stratification in patients with cirrhosis and future screening implementations.

Rates per 100 person-years for adverse events, infections, and major adverse cardiac events were similar between placebo and ustekinumab through up to 5 years.

Data show the proportion of individuals with sustained clinical cure through Week 8 was 80.3% with CP101 treatment.

BMI did not have an association with increased risk for death in any BMI category, according to study investigators.

A look into the efficacy of ozanimod in patients with UC and the potential risk for cardiovascular events.

Patients with IBD are often at an increased risk of developing NAFLD.

Dr. Blount discusses the DDW 2022 poster of distinction on the investigational live biotherapeutic.

Post-treatment, data show molecular age remained significantly greater than chronological age at a median difference of 18.6 years.

DASH diet was inversely associated with NAFLD risk, independent of BMI changes.

The treatment did not improve sustained virologic response but did increase the rate of treatment-related adverse events.

Dr. Chopra said an FDA-approved treatment for NAFLD could come in the next 6 months.

Alcohol use increased during the COVID-19 pandemic, leading to an increase in alcoholic hepatitis.

NAFLD is currently the most prevalent liver disease in the US.

Dr. Simonetto is involved in several studies using artificial intelligence.

The prevalence of NAFLD in the pediatric population has increased in recent years.

Using a main adjusted model, the investigators found an increase of 31.8 percentage points in test completion in the intervention group compared to the control group.

The guidelines replace risk-based reccomendations for adults between 19-59 years.

Investigators found 31% of patients treated with aldafermin 0.3 mg had an improvement in liver fibrosis of at least 1 stage with no worsening of NASH.

Alcohol use was additionally associated with worse fibrosis, but no interaction was noted between the two risk factors.

HCV genotype 4 non-a/d subtypes are common in sub-Saharan Africa.

Resmetirom is being studied as a potential treatment for both NAFLD and NASH.

As the number of entecavir manufacturers increased from 1-11, the NADAC decreased from $30.12 to $1.93 per 0.5 mg tablet.

There are several barriers that prevent better HCV care, including availability and access to diagnostic and monitoring tests and the requirement for frequent medical visits during treatment.

Exposure to long-term prescription opioid therapy was linked to a 3.2-fold higher risk of HCV seroconversion compared to individuals who were prescription opioid-naïve or acute.

Weight loss could be beneficial for NASH and NAFLD patients.

TARGET-NASH as now expanded into European centers.

The US recommended HBV vaccines to be part of the infant immunization plan in 1991.

The rigidity of hospital settings and a lack of awareness prevents better hepatitis C virus diagnoses in the homeless population.

The recombinant vaccine resulted in higher rates of seroprotection in all subjects, particularly those 45 years and older.